Sm_nuary Yttrium-90 chelated by the tetraphosphonate EDTMP achieved a high uptake in bone and a rapid clearance from all soft tissues compared with 90Y nitrilotriacetate, citrate and acetate. The biological half-life of 90Y in the bone was greater than 72h. but the quantity, and therefore dose, could be reduced by 50% using repeated, non-toxic chelation therapy with the calcium salt of DTPA. This treatment should be able to supplement current treatments for leukaemia where the dose of external beam radiation is associated with considerable morbidity.
Radiotherapy followed by allogeneic bone marrow transplantation is now a common procedure in the curative therapy of leukaemias. The amount of radiation which can be administered is limited by toxicity to certain radiosensitive soft tissues such as the lungs and gut. Shielding the lungs would unavoidably reduce the dose to leukaemic cells in the ribs and thus increase the possibility of relapse. Radioisotopes which can be targeted specifically to the skeleton offer attractive alternatives for marrow ablation, or alternatively they could be used in conjunction with lower dose external beam radiotherapy.
Such isotopes are now also under investigation for the palliation of bone pain associated with metastatic deposits of tumours of the breast and prostate and from pnrmary osteosarcoma. These include 1311 (as diphosphonate ; Eisenhut et al., 1986) , 89Sr (as the free ion; Blake et al., 1987) and '53Sm (as the tetraphosphonate complex; Goeckeler et al., 1987) , which localise efficiently in the bone and are cleared rapidly from all soft tissues. Successful pain reduction has been reported for all three isotopes, and in addition 89Sr has demonstrated enhanced uptake in certain osteoblastic tumours. Palliation results from toxic radiation doses to the periphery of the tumours from the isotopes deposited on hydroxyapatite mineral surfaces. Because of their low energies, the beta particle emissions from these isotopes have limited penetration into tumours or bone marrow spaces. However, 89mra = 1.5 MeV) has been shown to ablate medullary haemopoietic tissue at doses above 4yCi per g body weight in mice in several investigations (Klassen et al., 1972; Adler et al.. 1977) . A limitation to the clinical use of 89Sr, and also '31I results from a combination of their long physical half-lifes (50 and 7 days respectively), and long biological half-lives in bone. These factors prevent prompt bone marrow transplantation and graft establishment. For successful leukaemia and marrow ablation in humans, isotopes with substantially shorter half-lives and higher # particle energies are required.
Yttrium-90 is a high energy (2.3 MeV) beta emitter with a physical half-life of 2.7 days which has limited bone-seeking properties. Its physical properties make it ideal for therapeutic applications, the most energetic beta emission being able to penetrate to 1 cm from the site of deposition in soft tissue, with an average range of approximately 4mm. Theoretically, therefore, it can penetrate all marrow spaces in normal trabecular bone and conceivably even to the centre of large tumours where bone destruction may be extensive. A disadvantage of yttrium-90 is its tendency to accumulate in the reticuloendothelial system as well as hydroxyapatite surfaces, due to the formation of colloidal hydroxide or yttriumtransferrin complexes, followed by transport to the liver. The previous very limited studies of yttrium-90 (Dudley & Greenberg, 1956; Kutzner et al., 1983) have failed to reduce significantly the reticuloendothelial uptake, and its use as a Received 30 November 1988 , accepted 20 February 1989 radiotherapeutic bone agent has been disregarded in recent years. Since marrow ablative radiotherapy is becoming increasingly common in the management of leukaemia, there would appear to be a place for an isotope with the charactenstics of 90Y.
Specific deposition of yttrium into the skeleton demands its delivery in a chemical form with affinity for bone mineral alone. In the past, this has been difficult to achieve because even when chelated, liver uptake has been substantial, presumably because the stabilities of the complexes are insufficient to prevent transferrin binding or colloid formation in vivo. Ideally therefore, targeting agents are required with an intrinsically high affinity for bone, and also a high affinity for the yttrium ion. Compounds with these properties are the phosphonate analogues of polyaminocarboxylic acids, and one in particular (ethylene diamine tetra methylene phosphonate; EDTMP) has already been used to target 153Sm to bone mineral with considerable success (Goeckeler et al.. 1987) . Because of chemical similarities between yttrium and the rare earths, EDTMP should form stable complexes with yttrium and carry it-specifically to the bone with comparable efficiency. Here, 90Y-EDTMP complexes have been prepared and compared with other chelating agents for targeting 90Y to the bone in vivo. Similar experiments are also described using the gamma-emitter yttrium-88 to determine the effects of carrier yttrium on tissue distnrbution.
The adsorption of yttrium on hydroxyapatite is essentially irreversible under static conditions but elution in vivo is determined by rates of mineral resorption and new-bone formation. When considering its use in leukaemia therapy and bone marrow ablation, it would be advantageous to control the bone marrow dose by removing yttrium from the bone. Early studies aimed at lowering skeletal contamination by yttrium produced in nuclear accidents used repeated EDTA injections, and over a 14-day period, skeletal uptake was reduced to 70% of the control values (Cohn et al.. 1953). Conventionally, diethylene tnramine pentaacetic acid (DTPA) has been the agent of choice for the treatment of heavy metal overdose (Catsch, 1961) , and yttnrum also has a high affinity for this chelator. A further aim of this work was to manipulate the biological half-life of 90Y and 88Y in bone by chelation therapy using DTPA, and determine the amount of isotope that could be removed from skeletal tissue.
Materials and methods

Production of carrier-free yttriwn-90
A Dowex 50 W-X8 cation exchange column was loaded with ,20pCi 90Sr-mntrate and washed extensively with citric acid and 0.25M sodium acetate, pH6 as described by Vaughan et al. (1985) . It breakthrough of -2% was observed. The eluted 90Y acetate was used in subsequent preparations for injection into BALB/c mice.
Preparation of vttriwn isotope complexes and DTPA solutions Complexes of 90Y with the chelating agents citrate, nitrilotnracetate (NTA) and EDTMP were prepared. Up to 3 pCi of 90Y in acetate were added to solutions of tnrsodium citrate, and trisodium NTA (0.03ml) to give 1.5 x 10-5, 3 x 10-6 and 3 x 10-7 mol of chelator per injection. The volume of the injection was made to 0.18 ml with phosphate-buffered saline. EDTMP was a gift from Albright and Wilson Ltd and supplied at a purity of at least 92.7%, the main contaminant being ethylene diamine trimethylene phosphonate. It was used at concentrations of 0.54 mM (pH 4.5) and 54 mM (pH 3.9). Volumes of these solutions were added to 2 pCi 90Y to give 3.54x 10-8 or 1.77x 10-6mol per injection in a final volume of 0.18 ml, the remaining volume being made up with 0.25 M sodium acetate pH 5.9 and water.
The complex of yttrium-88 with EDTMP was also prepared in order to compare biodistributions with those of 90Y. Yttrium-88 (0.3 pCi in 5 pi 0.25 M acetate pH 6; Amersham, 0.98 mCi pg-1) was chelated with volumes of 0.5 M EDTMP (pH 6.95 in 0.5 M sodium chloride) after the addition of non-radioactive yttrium chloride to give either a 2-fold or 1.2-fold molar excess of EDTMP over yttrium. Immediately upon addition of EDTMP to the yttrium solution, a white precipitate formed which redissolved over a 10-min period. These solutions were diluted with 0.25M sodium acetate pH 6 to give final volumes of around 0.3 ml. They were used to evaluate the effect of increasing doses over carrier yttrium and EDTMP concentration on the biodistribution of yttrium in mice.
The calcium salt of DTPA was prepared by dissolving sodium chloride, sodium bicarbonate, calcium carbonate and DTPA in water to give 0.034M Na3CaDTPA in 0.9% saline (pH 8 The biodistribution of 88Y-EDTMP was determined in the same way except that injection volumes were 0.3 ml. Tissues were similarly counted but without the need for addition of water or correction due to counting geometry and 90Sr contamination.
The effect of DTPA on the biodistribution of both 90Y and 88Y was determined. Animals received an i.p. injection of 90Y-EDTMP or 88Y-EDTMP, and the following day either DTPA (0.2 ml, 6.8 pmol, test animals) or physiological saline (0.2 ml, controls). Several experiments were carried out in which animals were treated with up to eight DTPA injections over up to 4 days. Animals were killed at least 15 h after the final DTPA/saline injection, tissues being weighed and counted as described above, and the necessary corrections made to determine counts in %ID g-1 tissue. The significance of differences between treated and control counts in each tissue was calculated using a one-tailed Student's t test.
Dosimetry
Radiation doses to the skeleton in 25g mice assuming 20% ID g-were calculated using a computer model already described by Vaughan et al. (1987) , and modified to estimate bone marrow doses as described by Spiers (1978) . The effects of CaDTPA chelation therapy were calculated similarly but including the decorporation data. Calculations were based on the following assumptions: (a) tl'2 of skeletal accumulation = 0.5 h; (b) 
Results
With all the chelating agents tested, 90Y demonstrated a high absolute uptake in bone mineral. This was the case for tracer levels of carrier-free isotope. However, over the range of tested concentrations, citrate failed to significantly reduce reticuloendothelial uptake (Figure 1 ) and NTA failed similarly at low chelator concentrations, compared with unchelated isotope (Figure 2) . At the highest concentration tested, NTA suppressed both reticuloendothelial and bone mineral accumulation. This was also at a concentration which could prove unacceptably toxic if scaled up for clinical use. Over a range of concentrations, EDTMP enabled consistently high bone uptakes and low kidney and liver accumulation (Table  I and Figure 3) . Because of its consistency in giving high bone to soft tissue uptake ratios compared with other targeting agents, EDTMP was considered the reagent of choice for the specific delivery of 90Y to bone mineral, though absolute skeletal uptake was marginally lower (Figure 4) Time (h) Fgwe 6 Estimated cumulative radiation doses in bone marrow (Gy MBq-)'in mice given 90Y-EDTMP (a) and 90Y-EDTMP followed by chelation therapy with CaDTPA (b). both the bone mineral and the kidney and liver by CaDTPA was dependent on the number of doses given (Table III) . Maximum removal from the tissues in test animals compared with control animals was achieved by giving 2 x 6.8 umol CaDTPA daily over 3 days. In most cases, the treated animal tissue counts were significantly lower than the controls as judged by a one-tailed t-test. There was no improved clearance beyond this by giving 2 x 6.8 umol daily for 4 days. For high quantities of carrier yttrium (50pg) there was no significant mobilisation of activity from the skeleton with the same CaDTPA treatment regimen. The apparent maximum proportion of isotope cleared from the bone was 50% and from the kidney and liver approximately 70% in the optimum cases. This maximum mobilisation could be achieved by 5 days from the initial isotope injection.
Radiation doses administered by 90Y-EDTMP to the bone marrow were expressed as either cGy h -MBq-I ( Figure 5 ) or cumulative doses (Gy total MBq-1, Figure 6 ). Calcium DTPA reduced the dose but no decorporation effects were observed subsequent to six CaDTPA injections.
Discws
Yttnrum-90 has been selectively targeted to bone in mice using citrate, the tricarboxylate NTA and EDTMP. It was found that all reagents successfully enabled bone deposition but EDTMP gave the lowest corresponding doses to all soft tissues. This was due to the high stability of the yttrium-EDTMP complex allied to the natural bone-seeking qualities of EDTMP. It showed a very similar biodistribution to the lanthanide isotope EDTMP complexes (Goeckeler et al., 1987; Appelbaum et al., 1988) . Yttrium-EDTMP itself has a high affinity for bone comparable with the diphosphonates, as shown by previous studies with other isotopes in rats (Goeckeler et al., 1987) . Similar bone accumulation by the complex was shown over a range of 90Y-EDTMP concen- (Keeling & Vaughan. 1988 ).
The results of yttrium targeting described are applicable to both trace quantities of carrier-free isotope and for preparations containing quantities of non-active material, though the chelate to yttrium ratio does affect bone targeting at high levels of yttrium carrier. The reduction in bone uptake and increased excretion can be attributed to the saturation of adsorption sites in the skeleton. For producing therapeutic millicurie doses, the 90Sr/90Y generator system (Vaughan et al.. 1985) 
